311 related articles for article (PubMed ID: 25415869)
1. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
2. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
3. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
Gul M; Fakhar M; Najumuddin ; Rashid S
PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.
Crawford JJ; Lee W; Aliagas I; Mathieu S; Hoeflich KP; Zhou W; Wang W; Rouge L; Murray L; La H; Liu N; Fan PW; Cheong J; Heise CE; Ramaswamy S; Mintzer R; Liu Y; Chao Q; Rudolph J
J Med Chem; 2015 Jun; 58(12):5121-36. PubMed ID: 26030457
[TBL] [Abstract][Full Text] [Related]
6. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
7. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
8. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
9. Role of p21-activated kinases in cardiovascular development and function.
Kelly ML; Astsaturov A; Chernoff J
Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
[TBL] [Abstract][Full Text] [Related]
10. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
[TBL] [Abstract][Full Text] [Related]
11. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.
Han D; Wang H; Cui W; Zhang B; Chen BZ
Future Med Chem; 2020 Mar; 12(5):367-385. PubMed ID: 32064922
[No Abstract] [Full Text] [Related]
12. The role of p21-activated kinases in pancreatic cancer.
Yeo D; He H; Baldwin GS; Nikfarjam M
Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors.
Hao C; Zhao F; Song H; Guo J; Li X; Jiang X; Huan R; Song S; Zhang Q; Wang R; Wang K; Pang Y; Liu T; Lu T; Huang W; Wang J; Lin B; He Z; Li H; Li F; Zhao D; Cheng M
J Med Chem; 2018 Jan; 61(1):265-285. PubMed ID: 29190083
[TBL] [Abstract][Full Text] [Related]
14. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity.
Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS
Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of Targeting PAK Signaling.
Senapedis W; Crochiere M; Baloglu E; Landesman Y
Anticancer Agents Med Chem; 2016; 16(1):75-88. PubMed ID: 26081410
[TBL] [Abstract][Full Text] [Related]
16. Role of p-21-activated kinases in cancer progression.
King H; Nicholas NS; Wells CM
Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727
[TBL] [Abstract][Full Text] [Related]
17. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
[TBL] [Abstract][Full Text] [Related]
18. The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor.
Park JK; Kim S; Han YJ; Kim SH; Kang NS; Lee H; Park S
Bioorg Med Chem Lett; 2016 Jun; 26(11):2580-3. PubMed ID: 27117431
[TBL] [Abstract][Full Text] [Related]
19. UnPAKing the class differences among p21-activated kinases.
Eswaran J; Soundararajan M; Kumar R; Knapp S
Trends Biochem Sci; 2008 Aug; 33(8):394-403. PubMed ID: 18639460
[TBL] [Abstract][Full Text] [Related]
20. NMR binding and crystal structure reveal that intrinsically-unstructured regulatory domain auto-inhibits PAK4 by a mechanism different from that of PAK1.
Wang W; Lim L; Baskaran Y; Manser E; Song J
Biochem Biophys Res Commun; 2013 Aug; 438(1):169-74. PubMed ID: 23876315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
